Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) will release its first quarter 2022 financial results on May 9, 2022, after U.S. market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and business updates. Interested parties can access the webcast on the company's website. Syndax's pipeline includes promising cancer therapies such as SNDX-5613, a Menin–MLL inhibitor, axatilimab, a CSF-1 receptor blocker, and entinostat, a class I HDAC inhibitor.

Positive

• Upcoming Q1 2022 financial results expected to provide insights into company performance.
• Innovative pipeline including SNDX-5613, axatilimab, and entinostat.

Negative

• None.

WALTHAM, Mass., May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results on Monday, May 9, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 9, to discuss the Company's financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 1394554
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/49kx4w4n

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464

SNDX-G

 

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-may-9-2022-301536956.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals release its first quarter 2022 financial results?

Syndax Pharmaceuticals will release its first quarter 2022 financial results on May 9, 2022.

What time is the conference call for Syndax's Q1 2022 financial results?

The conference call for Syndax's Q1 2022 financial results is scheduled for 4:30 p.m. ET on May 9, 2022.

How can I access the webcast for Syndax's Q1 2022 financial results?

The webcast can be accessed through Syndax's website on the Events & Presentations page under the Investors section.

What are some key therapies in Syndax's pipeline?

Syndax's pipeline includes SNDX-5613, axatilimab, and entinostat.